38 related articles for article (PubMed ID: 25088227)
1. Increased hippocampal epigenetic age in the Ts65Dn mouse model of Down Syndrome.
Ravaioli F; Stagni F; Guidi S; Pirazzini C; Garagnani P; Silvani A; Zoccoli G; Bartesaghi R; Bacalini MG
Front Aging Neurosci; 2024; 16():1401109. PubMed ID: 38836050
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
García-Cerro S; Martínez P; Vidal V; Corrales A; Flórez J; Vidal R; Rueda N; Arbonés ML; Martínez-Cué C
PLoS One; 2014; 9(9):e106572. PubMed ID: 25188425
[TBL] [Abstract][Full Text] [Related]
3. Comparative proteomic profiling reveals aberrant cell proliferation in the brain of embryonic Ts1Cje, a mouse model of Down syndrome.
Ishihara K; Kanai S; Sago H; Yamakawa K; Akiba S
Neuroscience; 2014 Dec; 281():1-15. PubMed ID: 25261685
[TBL] [Abstract][Full Text] [Related]
4. Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.
Alldred MJ; Lee SH; Petkova E; Ginsberg SD
J Comp Neurol; 2015 Jan; 523(1):61-74. PubMed ID: 25131634
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of trisomy and pharmacologic modulation on structural, functional, molecular, and genetic systems in a Down syndrome mouse model.
Llambrich S; Tielemans B; Saliën E; Atzori M; Wouters K; Van Bulck V; Platt M; Vanherp L; Gallego Fernandez N; Grau de la Fuente L; Poptani H; Verlinden L; Himmelreich U; Croitor A; Attanasio C; Callaerts-Vegh Z; Gsell W; Martínez-Abadías N; Vande Velde G
Elife; 2024 Mar; 12():. PubMed ID: 38497812
[TBL] [Abstract][Full Text] [Related]
6. Transcranial Direct Current Stimulation in neurogenetic syndromes: new treatment perspectives for Down syndrome?
Faralli A; Fucà E; Lazzaro G; Menghini D; Vicari S; Costanzo F
Front Cell Neurosci; 2024; 18():1328963. PubMed ID: 38456063
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations.
Lanz B; Abaei A; Braissant O; Choi IY; Cudalbu C; Henry PG; Gruetter R; Kara F; Kantarci K; Lee P; Lutz NW; Marjańska M; Mlynárik V; Rasche V; Xin L; Valette J; ;
NMR Biomed; 2020 Aug; ():e4325. PubMed ID: 33565219
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome).
Cárdenas AM; Fernández-Olivares P; Díaz-Franulic I; González-Jamett AM; Shimahara T; Segura-Aguilar J; Caviedes R; Caviedes P
Neurotox Res; 2017 Nov; 32(4):614-623. PubMed ID: 28695546
[TBL] [Abstract][Full Text] [Related]
9. The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.
Contestabile A; Magara S; Cancedda L
Front Cell Neurosci; 2017; 11():54. PubMed ID: 28326014
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Magnetic Resonance Imaging and Spectroscopy Studies of Memory, Aging, and Cognitive Decline.
Febo M; Foster TC
Front Aging Neurosci; 2016; 8():158. PubMed ID: 27468264
[TBL] [Abstract][Full Text] [Related]
11. Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.
Hamlett ED; Boger HA; Ledreux A; Kelley CM; Mufson EJ; Falangola MF; Guilfoyle DN; Nixon RA; Patterson D; Duval N; Granholm AC
Curr Alzheimer Res; 2016; 13(1):35-52. PubMed ID: 26391050
[TBL] [Abstract][Full Text] [Related]
12. Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study.
Nie X; Hamlett ED; Granholm AC; Hui ES; Helpern JA; Jensen JH; Boger HA; Collins HR; Falangola MF
Magn Reson Imaging; 2015 May; 33(4):437-47. PubMed ID: 25527393
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
[TBL] [Abstract][Full Text] [Related]
14. Comparison of in vivo and in situ detection of hippocampal metabolites in mouse brain using
Hsu CH; Lin S; Ho AC; Johnson TD; Wang PC; Scafidi J; Tu TW
NMR Biomed; 2021 Feb; 34(2):e4451. PubMed ID: 33258202
[TBL] [Abstract][Full Text] [Related]
15. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
16. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.
Baruth JM; Wall CA; Patterson MC; Port JD
Autism Res; 2013 Apr; 6(2):119-33. PubMed ID: 23436782
[TBL] [Abstract][Full Text] [Related]
17. Precision of metabolite-selective MRS measurements of glutamate, GABA and glutathione: A review of human brain studies.
Kanagasabai K; Palaniyappan L; Théberge J
NMR Biomed; 2024 Mar; 37(3):e5071. PubMed ID: 38050448
[TBL] [Abstract][Full Text] [Related]
18. In vivo 1H MRS study in microlitre voxels in the hippocampus of a mouse model of Down syndrome at 11.7 T.
Santin MD; Valabrègue R; Rivals I; Pénager R; Paquin R; Dauphinot L; Albac C; Delatour B; Potier MC
NMR Biomed; 2014 Oct; 27(10):1143-50. PubMed ID: 25088227
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
